Search company, investor...
Rox Medical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series E | Dead

Total Raised


Last Raised


About Rox Medical

ROX Medical is an early phase medical device company that is developing a treatment for Chronic Obstructive Pulmonary Disease (COPD). The company's therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula. The company\'s device creates a passage between an artery and a vein in the pelvic region which redirects oxygen rich blood back to the lungs of severe COPD patients.

Rox Medical Headquarters Location

150 Calle Iglesia Suite A

San Clemente, California, 92672,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Rox Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rox Medical is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Rox Medical Patents

Rox Medical has filed 40 patents.

The 3 most popular patent topics include:

  • Respiratory therapy
  • Lung disorders
  • Muscarinic antagonists
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Lung disorders, Respiratory therapy, Rare diseases, Muscarinic antagonists


Application Date


Grant Date



Related Topics

Vascular diseases, Lung disorders, Respiratory therapy, Rare diseases, Muscarinic antagonists



Latest Rox Medical News

ROX Medical, Inc. Hires Dr. Sackner-Bernstein as CMO and Executive VP of Clinical and Regulatory...

Dec 18, 2018

News provided by Share this article SAN CLEMENTE, Calif., Dec. 18, 2018 /PRNewswire/ -- ROX Medical, Inc. (ROX), a privately held medical device company pioneering a minimally-invasive therapy for hypertension, today announced the appointment of Jonathan Sackner-Bernstein, MD as its Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs. Dr. Sackner-Bernstein brings experiences as engineer, cardiologist, clinical investigator, regulator and innovator to the ROX team. Following his academic career (primarily at Columbia University), Sackner-Bernstein shifted to developing his product development skills. He built and ran a Phase 1 clinical research unit, served in a senior role at the FDA, ran clinical/regulatory for a stem cell therapeutic and consulted for DARPA. Prior to joining ROX, Sackner-Bernstein served as consultant to a wide range of device, drug and biologic companies. Dr. Sackner-Bernstein was recruited to the FDA's Center for Devices as the number 2 in scientific/clinical matters. He led teams across a diverse portfolio – spanning from innovation programs to the post-market safety transformation. Sackner-Bernstein led several Center and Agency level interactions with other Federal Agencies and international regulatory authorities. Following separation from Federal service, Sackner-Bernstein was recruited by DARPA to support the launch of their new Biological Technologies Office. "Dr. Sackner-Bernstein is a broadly experienced physician and seasoned medical device executive with clinical, FDA and medical device company background," commented CEO Michael MacKinnon. "We are thrilled to have Dr. Sackner-Bernstein join the executive team at ROX Medical to progress this exciting technology to the market and potentially become the standard of care in hypertension." "The ROX Coupler represents a transformative opportunity in the treatment of hypertension," explained Sackner-Bernstein. "As angioplasty forever altered the management of coronary disease, so I believe ROX has the opportunity to do for hypertension. Who wouldn't want to join the team in such a pursuit?" About ROX Medical, Inc. ROX® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system. The ROX Coupler is a small stent-like device that is placed between the artery and vein located in the upper thigh. The Coupler is about the size of a dime and is easily placed using standard catheter techniques. ROX Medical is conducting the CONTROL HTN-2 clinical trial in the United States for hypertension (visit  for more information). The ROX Medical Coupler is commercially available in Europe under CE mark. SOURCE ROX Medical, Inc

  • Where is Rox Medical's headquarters?

    Rox Medical's headquarters is located at 150 Calle Iglesia, San Clemente.

  • What is Rox Medical's latest funding round?

    Rox Medical's latest funding round is Series E.

  • How much did Rox Medical raise?

    Rox Medical raised a total of $97.7M.

  • Who are the investors of Rox Medical?

    Investors of Rox Medical include Versant Ventures, Domain Associates, Novartis Venture Funds, Apple Tree Partners, Prism VentureWorks and 3 more.

  • Who are Rox Medical's competitors?

    Competitors of Rox Medical include Aethlon Medical, Mimedx, HistoSonics, Celonova Biosciences, Uptake Medical and 15 more.

You May Also Like


Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.


synecor is a medical device developer

Leptos BioMedical

Leptos Biomedical is developing an impressive new electrical stimulation device treating obesity.


Traumatec offers a patented, non-invasive device to cool the brain

HistoSonics Logo

HistoSonics develops a device that uses ultrasound pulses to treat prostate disease. The device is a non-invasive soft tissue ablation modality that mechanically homogenizes target tissue resulting in complete cellular destruction. As a non-thermal modality, histotripsy ablates tissue with no thermal injury. The liquefied tissue is absorbed or voided without remnants or scarring.


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.